ArticleJournal of molecular medicine (Berlin, Germany)2025
Oral supplementation of melatonin attenuates the onset of alcohol-related liver disease.
Article in Journal of molecular medicine (Berlin, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The potential protective mechanisms of melatonin on alcoholic fatty liver disease based on the animal study.Frontiers in veterinary science · 2026Article
- Melatonin Improves Intestinal Barrier Impairment in a Mouse Model of Autism Spectrum Disorder.Biology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Studies suggest that supplementing melatonin in pharmacological doses may attenuate the development of liver diseases including alcohol-related liver diseases (ALD) in model organisms. If melatonin at "physiological" doses achievable through the intake of foods and beverages affects the development of liver diseases, it has not yet been clarified; therefore, we assessed whether supplementing "dietary doses" of melatonin affects the development of ALD in mice. Female 6-8-week-old C57BL/6J mice were either pair-fed a liquid alcohol-enriched Lieber DeCarli diet or a control diet ± melatonin (50 ng/kg BW/day) for 6 weeks. Markers of liver damage and intestinal barrier function were assessed. Moreover, the effects of melatonin on intestinal barrier function were assessed in an ex vivo model. Supplementing melatonin significantly attenuated the development of ALD being related to lower interleukin-6 protein, NOx, and 4-hydroxynonenal protein adduct levels in liver tissue. Impairments of intestinal barrier function in small intestine in ethanol-fed mice were significantly attenuated in ethanol-fed mice treated with melatonin being associated with lower NOx and higher phosphorylation levels of AMPK. In summary, our results suggest that an oral supplementation of "dietary" doses of melatonin may dampen the development of ALD in mice. KEY MESSAGES: Supplementation of "dietary" doses of melatonin dampens the development of ALD. Melatonin attenuates alcohol-induced small intestinal barrier dysfunction. Protective role of melatonin is related to alterations of AMPK activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.